Loading...
Alzamend Neuro Inc (ALZN) is not a strong buy at the moment for a beginner investor with a long-term strategy. The lack of positive financial performance, no significant trading trends, and absence of recent news or catalysts make this stock a hold rather than a buy. Additionally, no proprietary trading signals or options data support a strong entry point.
The MACD is positive and expanding, suggesting mild bullish momentum. However, the RSI is neutral at 62.805, and moving averages are converging, indicating no clear trend. The stock is trading near its R1 resistance level of 2.111, which may act as a barrier to further upward movement.
NULL identified. No recent news or significant trading trends from hedge funds or insiders.
The company's financial performance is weak, with a significant YoY drop in net income (-29.29%) and EPS (-91.69%). Additionally, the market sentiment is neutral, with no recent news or trading trends to drive the stock upward.
In Q2 2026, revenue remained at 0 with no growth. Net income dropped to -1,000,758 (-29.29% YoY), and EPS declined significantly to -0.3 (-91.69% YoY). Gross margin remained at 0 with no improvement.
No data available for analyst ratings or price target changes.